COMMUNIQUÉS West-GlobeNewswire

Sanara MedTech Inc. Announces Fourth Quarter and Full Year 2023 Results
25/03/2024
FORT WORTH, TX, March 25, 2024 (GLOBE NEWSWIRE) -- Sanara MedTech Inc . Based in Fort Worth, Texas, Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “our” or “us”) (NASDAQ: SMTI), a medical technology company focused [...]
QIAGEN introduces QIAstat-Dx Analyzer 2.0 with remote test results access, enhancing collaboration across healthcare system
25/03/2024
QIAstat-Dx Analyzer 2.0 with Software 1.6 release enables mobile access to test results, streamlining diagnostic processes and enhancing patient care // QIAstat-Dx Analyzer 2.0 also offers enhanced epidemiology [...]
NKGen Biotech Presents Additional Phase 1 Clinical Trial Data in Alzheimer’s Disease at the Tau2024 Global Conference
25/03/2024
SNK01 autologous NK cell therapy demonstrated a positive effect on cerebral spinal fluid (“CSF”) and plasma Tau proteins in Alzheimer’s patients. The additional Phase 1 SNK01 trial data suggest clinical activity [...]
OpGen Announces Acquisition of Preferred Stock by David Lazar
25/03/2024
David Lazar invests $3 million in Preferred Stock New OpGen Board of Directors appointed David Lazar will take over as CEO of OpGen OpGen settles outstanding liabilities with EIB ROCKVILLE, Md., March 25, 2024 (GLOBE [...]
Praxis Precision Medicines to Host PRAX-628 Program Update
25/03/2024
Presentation will be held virtually on Tuesday, March 26, 2024 at 8:00 a.m. ET Praxis leadership will be joined by key opinion leader in epilepsy Dr. Daniel Friedman, Professor of Neurology at NYU Grossman School of [...]
BioCryst to Present at Upcoming Investor Conferences
25/03/2024
RESEARCH TRIANGLE PARK, N.C., March 25, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present at the H.C. Wainwright 2 nd Annual Autoimmune & [...]
eFFECTOR Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
25/03/2024
Topline data from the randomized Phase 2b KICKSTART trial of tomivosertib combined with pembrolizumab in non-small cell lung cancer (NSCLC) expected in early April 2024 Median progression free survival (mPFS) of 7.4 [...]
OXURION announces its presence at the Paris SmallCap event on March 28, 2024.
25/03/2024
OXURION announces its presence at the Paris SmallCap event on March 28, 2024. Leuven, BELGIUM - March 25, 2024 - 7:00 p.m, Oxurion NV (Euronext Brussels : OXUR), a Leuven-based biopharmaceutical company, is pleased to [...]
ONWARD® Medical Publishes Closing of Accelerated Bookbuild Offering and Public Offering in France
25/03/2024
NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE [...]
Foreløbige tal for 2023 og finansielle forventninger til 2024
25/03/2024
Revisionen af selskabets årsrapport for 2023 er ikke afsluttet. Årsrapporten offentliggøres på onsdag den 27. marts 2024 i henhold til selskabets finanskalender. Selskabet har opnået følgende foreløbige resultater for [...]
Gedeon Richter Selects Trial Interactive for Clinical Trial Management
25/03/2024
Specialty Pharmaceutical Company Deploys TransPerfect Technology to Streamline TMF Operations BUDAPEST, Hungary and NEW YORK, March 25, 2024 (GLOBE NEWSWIRE) -- TransPerfect Life Sciences , a leading global provider of [...]
Once Esteemed Institutions Are Corrupted, States President of the Association of American Physicians and Surgeons (AAPS)
25/03/2024
TUCSON, Ariz., March 25, 2024 (GLOBE NEWSWIRE) -- The institutions and experts we have long relied on are now contaminated with intellectual, moral, and ethical rot, writes ophthalmologist Jane Lindell Hughes , M.D., F. [...]
SAB Biotherapeutics Announces Clinical Partnership with Naval Medical Research Center to Advance Potential Influenza Treatment
25/03/2024
SIOUX FALLS, S.D., March 25, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS ), (“SAB” or the “Company”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is [...]
Type 1 diabetes researchers from across Canada sign letter of support for diabetes research to be included in the upcoming federal budget
25/03/2024
TORONTO, March 25, 2024 (GLOBE NEWSWIRE) -- Top researchers in the field of type 1 diabetes (T1D) signed an open letter in support of renewed funding for the JDRF-CIHR Partnership to Defeat diabetes through Federal [...]
Des chercheurs sur le diabète de type 1 de partout au Canada signent une lettre de soutien pour que la recherche sur le diabète soit incluse dans le prochain budget fédéral
25/03/2024
TORONTO, 25 mars 2024 (GLOBE NEWSWIRE) -- Des chercheurs de premier plan dans le domaine du diabète de type 1 (DT1) ont signé une lettre ouverte en faveur du renouvellement du financement du Partenariat FRDJ-IRSC pour [...]
Transactions in Connection with Share Buy-back Program
25/03/2024
Company Announcement COPENHAGEN, Denmark; March 25, 2024 – Genmab A/S (Nasdaq: GMAB). On March 15, 2024, Genmab announced the initiation of a share buy-back program to repurchase up to DKK 3.5 billion worth of shares. [...]
Revive Drip’s Expert IV Nurses Bring Alternative Wellness Solutions to the Greater Puget Sound Area
25/03/2024
Revive Drip delivers fast and effective IV hydration in the comfort of your home. GIG HARBOR, WA, March 25, 2024 (GLOBE NEWSWIRE) -- Revive Drip, a leading mobile intravenous therapy (IV) company providing customized [...]
Clinical Data on the Impact of Sotagliflozin on Stroke and Heart Attack Risk Among Four Lexicon-Sponsored Presentations at the American College of Cardiology 73rd Annual Scientific Session & Expo
25/03/2024
THE WOODLANDS, Texas, March 25, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that four data presentations related to sotagliflozin, an inhibitor of two sodium glucose transport [...]
Cassava Sciences Announces Completion of an Interim Safety Review of Oral Simufilam On-going Phase 3 Trials
25/03/2024
An Independent Data and Safety Monitoring Board (DSMB) Recently Evaluated the Interim Patient Safety Database for Oral Simufilam in On-going Phase 3 Trials. The DSMB Recommended Both Phase 3 Trials Continue as Planned, [...]

Pages